MA38302A1 - Anti-pdgfr-beta antibodies and their uses - Google Patents

Anti-pdgfr-beta antibodies and their uses

Info

Publication number
MA38302A1
MA38302A1 MA38302A MA38302A MA38302A1 MA 38302 A1 MA38302 A1 MA 38302A1 MA 38302 A MA38302 A MA 38302A MA 38302 A MA38302 A MA 38302A MA 38302 A1 MA38302 A1 MA 38302A1
Authority
MA
Morocco
Prior art keywords
pdgfr
beta
antibodies
diseases
bind
Prior art date
Application number
MA38302A
Other languages
French (fr)
Other versions
MA38302B1 (en
Inventor
Stanley Wiegand
Ivan Lobov
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from PCT/US2014/010395 external-priority patent/WO2014109999A1/en
Publication of MA38302A1 publication Critical patent/MA38302A1/en
Publication of MA38302B1 publication Critical patent/MA38302B1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps qui se lient au récepteur bêta du facteur de croissance issu des plaquettes (pdgfr-bêta) et des procédés de leur utilisation. Selon certains modes de réalisation de l'invention, les anticorps sont des anticorps complètement humains qui se lient à pdgfr-bêta humain avec une affinité élevée. Les anticorps de l'invention sont utiles pour le traitement de maladies et de troubles associés à la signalisation par pdgfr-bêta et/ou l'expression cellulaire de pdgfr-bêta, tels que des maladies oculaires, des maladies fibrotiques, des maladies vasculaires et le cancer.The present invention relates to antibodies that bind to platelet-derived growth factor beta receptor (pdgfr-beta) and methods of their use. In some embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with pdgfr-beta signaling and / or cellular expression of pdgfr-beta, such as ocular diseases, fibrotic diseases, vascular diseases and the like. the cancer.

MA38302A 2013-01-09 2014-01-07 Anti-pdgfr-beta antibodies and their uses MA38302B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750437P 2013-01-09 2013-01-09
PCT/US2014/010395 WO2014109999A1 (en) 2013-01-09 2014-01-07 ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF

Publications (2)

Publication Number Publication Date
MA38302A1 true MA38302A1 (en) 2018-02-28
MA38302B1 MA38302B1 (en) 2018-10-31

Family

ID=56117360

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38302A MA38302B1 (en) 2013-01-09 2014-01-07 Anti-pdgfr-beta antibodies and their uses

Country Status (2)

Country Link
AR (1) AR094379A1 (en)
MA (1) MA38302B1 (en)

Also Published As

Publication number Publication date
AR094379A1 (en) 2015-07-29
MA38302B1 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
MA42622B1 (en) LIAISONS IN TIGIT AND THEIR USES
MY202018A (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
MA45125B1 (en) Anti-alpha-synuclein antibodies and their uses
MA39313A1 (en) Anti-egfrviii antibodies and their uses in the treatment of various cancers
MA44659B1 (en) ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
MA44312A (en) ANTIBODIES AND THEIR METHODS OF USE
MA40041A (en) ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE
MA47313A (en) SUBCUTANEOUS FORMULATIONS OF HER2 ANTIBODIES
MY169165A (en) Anti-pdgfr-beta antibodies and uses thereof
MA40497A (en) ANTIBODIES AND CHEMERICAL ANTIGENIC RECEPTORS SPECIFIC TO CD19
MA33534B1 (en) Human antibodies have a high affinity against human 2 angiobots
MX2020011546A (en) Anti-msr1 antibodies and methods of use thereof.
MA37945B1 (en) Human antibodies to gfr3 and methods of use thereof
MA38961A1 (en) 3-phenyl-1h-pyrazolo [3,4-d] pyrimidin-4-ylamine compounds substituted for the crude tyrosine kinase inhibitors used to treat, for example, autoimmune, respiratory and inflammatory diseases, cancer, mastocytosis and osteoporosis
MA32566B1 (en) ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUSES AND USES THEREOF
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
MA34277B1 (en) PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
MX2013003468A (en) Anti-cd48 antibodies and uses thereof.
MA44334A (en) ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
PL1830881T3 (en) Combining therapies targeting multiple toll-like receptors and use thereof
MA49727A (en) ANTIBODIES AND POLYPEPTIDES DIRECTED AGAINST CD127
JOP20210323A1 (en) Multispecific heavy chain antibodies binding to cd22 and cd3
MX2018013072A (en) Tl1a antibodies and uses thereof.
MA39342B2 (en) Il -21 antibody
MX2022016342A (en) Multi-specific antibodies binding to bcma.